Latest Communications

07 July 2010
MonoSol Rx Announces FDA Approval of Zuplenz® Oral Soluble Film for Treatment of Nausea and Vomiting

15 June 2010
APR Applied Pharma Research s.a. of Switzerland launches its new corporate website and announces key strategic changes in its Business Model to better compete in the rapidly changing Healthcare industry

09 June 2010
MonoSol Rx and APR Applied Pharma Research s.a. Expand Joint Collaboration Agreement to develop and commercialize film formulations of prescription products


oral

Oral

APR has a long experience in the oral pharmaceutical and nutraceutical formulations: a dynamic approach coupled with a solid background enables APR to offer the best and the most complete R&D support starting from galenic phase to a complete Dossier ready for filing.

APR has many years experience on the following pharmaceutical dosage forms:
> Conventional tablets
> Bi-layer tablets
> Micro-tablets
> Capsules
> Granulates
> Oral Dispersible Film (ODF)
> Oral Dispersible Tablets (ODT)
> Oral Dispersible Powder (ODP)

About Release Profile, APR is able to work and design the following profiles:
> Conventional release
> Immediate release
> Fast release
> Delayed release
> Dual Release (Fast and Extended)
> Prolonged/Extended release
> Taste masked formulation

About manufacturing processes, APR's experience ranges through all the following techniques:
> Direct Compression;
> Dry and Wet Granulation;
> Melt granulation;
> Cosmetic and Functional coating.




Search results